InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $2.140 -0.71 (-24.91%)+
Announcement
Release
14 May 2026 9:43AM
Price at Release
$2.850
Full Release
download
Summary
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, announced receiving a $9.8 million R&D Tax Incentive refund. This refund is part of the Australian Federal Government’s R&D Tax Incentive program, which supports companies investing in R&D activities via a refundable tax offset. The received funds will help further develop Clarity's Targeted Copper Theranostic platform, which aims to enhance treatment outcomes for cancer patients. The company, listed as CU6 on ASX, emphasizes its commitment to advancing cancer care through innovative research and development.
Key Points
  • Clarity Pharmaceuticals received $9.8 million R&D Tax Incentive refund.
  • Refund is part of Australian Government's R&D Tax Incentive program.
  • Funds will aid in developing Targeted Copper Theranostic platform.
  • Clarity is focused on improving cancer treatment outcomes.
  • Clarity is a clinical-stage radiopharmaceutical company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.